The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue – Labiotech.eu (blog)
Labiotech.eu (blog) |
The CAR–T Race is Far from Over: This CEO is Exploring a New Avenue
Labiotech.eu (blog) Gilead has just splashed out $12 billion for Kite Pharma, and Ihe FDA is currently reviewing Novartis' Marketing Approval Application for the first-ever CAR–T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech … |
